Matt Robers, Promega

We will describe the application of an energy transfer technique (NanoBRET) that enables the first live cell approach to broadly profile compound fractional occupancy and residence time against a variety of target classes including kinases, integral membrane proteins, and E3 ligases.

Hannes Hahne, OmicScouts

Preclinical stages in the drug discovery process require a multitude of biochemical and genetic assays in order to characterize the effects of drug candidates on cellular systems and model organisms. The identification and deconvolution of drug targets and off-targets remains a key challenge in both phenotypic screening- as well as target-based drug discovery.

Ulfert Rand, Helmholtz Centre for Infection Research, Braunschweig

A highly dynamic gene activation process begins upon entry of CMV genomes into the host cell nucleus, both on the viral and on the host-cell side. The timing and velocity of gene expression events follow distinct patterns, but are also subject to considerable cell-to-cell heterogeneity. Experimental models to assess the dynamics of these processes at singlecell levels – and thus understand the processes shaping viral gene expression during the lytic cycle – are limited.

Michael Dabrowski, Pelago Bioscience

CETSA allows physiological relevant quantification of target engagement, which is prerequisite for achieving the intended efficacy. Therefore CETSA has during the last 8 years been applied from early target validation to analysis of clinical samples.

Hauke Cornils, Evotec

Phenotypic screening approaches provide the possibility to identify novel small molecules based on the desired cellular effects in an unbiased fashion. However, despite progress in the development and analysis of phenotypic screens, the identification of the molecular targets of screening ‚hits‘ provide a significant technical hurdle.